Skip to content
Stop using now Drug recall · FDA · Published March 22, 2019

InvaGen Testosterone Cypionate Injection Recall: Particulate Matter Hazard

InvaGen Pharmaceuticals recalls testosterone cypionate injections with particulate matter. Affected lots manufactured in India and shipped to US. Stop using immediately if you have the recalled product.

🇺🇸 FDA recall #D-1125-2019DrugInvaGen Pharmaceuticals ›
Take action

Contact the company

Recalling firmInvaGen Pharmaceuticals, Inc.550 S Research Pl · Central Islip, NY 11722-4415
✎ GovInfoNow plain-language explainer

InvaGen Pharmaceuticals is recalling testosterone cypionate injections that may contain particulate matter. This could cause serious injury if injected. The recall affects specific lots manufactured between 2019 and 2020. Read more at govinfonow.com/recall/39073-invagen-testosterone-cypionate-injection-recall-particulate-matter-hazard.

Source Summary by GovInfoNow · govinfonow.com/recall/39073-invagen-testosterone-cypionate-injection-recall-particulate-matter-hazard · Updated October 5, 2026 · FDA enforcement record: FDA #D-1125-2019

Cite this page

“InvaGen Testosterone Cypionate Injection Recall: Particulate Matter Hazard.” GovInfoNow, updated October 5, 2026. https://govinfonow.com/recall/39073-invagen-testosterone-cypionate-injection-recall-particulate-matter-hazard. Based on FDA recall #D-1125-2019 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1125-2019%22&limit=1).

The FDA announced on March 22, 2019, that InvaGen Pharmaceuticals, Inc. voluntarily recalled Testosterone Cypionate Injection due to the presence of particulate matter. The agency classified the recall as Class II.

How to tell if you have it

  • Brand: InvaGen Pharmaceuticals
  • Product: Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only
  • NDC: 69097-536-37
  • Lots: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020
  • Quantity: 75,968 vials

The hazard

The recall addresses the presence of particulate matter in the injection. The FDA classified the action as a Class II recall.

Context

GovInfoNow's records show InvaGen Pharmaceuticals, Inc. has 7 other recalls on record since March 5, 2018. Other recent recalls of similar products include Asteria Health Testosterone Pellets Recall (Jan. 26, 2026), B. Braun Medical Lactated Ringer's Injection Recall (April 28, 2026), and Sunny Pharmtech Cyclophosphamide Injection Recall (July 17, 2026).

How to tell if you have this one

Check the lot numbers on the vial: GH80216 (expires 1/2020), GH80322/GH80323 (expires 2/2020), or GH90072 (expires 12/2020). The product is a 10 mL vial for intramuscular use only.

  • Brand
    InvaGen Pharmaceuticals
  • Category
    Drug
FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class II
  • Status
    Terminated
  • Distribution
    Nationwide in the U.S.A.
  • NDC
    69097-536-37, 69097-537-37, 69097-537-31
Recall numberProduct, codes & lotsQuantity
D-1123-2019Testosterone Cypionate Injection, USP, 2000 mg/10 mL (200 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-537-37.; Lot #: GH80159, GH80160, GH80161 Exp 01/2020; GH80489, GH80490, GH80502, GH80503, GH80504 Exp 03/2020; GH80557, GH80598, GH80601, GH80602 Exp 04/2020; GH80845, GH80846, GH80855, GH80856, GH80857, GH80877 Exp 06/2020; GH80903, GH80908, GH80931 Exp 07/2020; GH81047 Exp 08/2020.12234 vials
D-1124-2019Testosterone Cypionate Injection, USP, 200 mg/mL, For IM use only, 1 mL Vial, Single Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-537-31.; Lot #:GH80009, GH80010, GH80011 Exp 12/2019; GH80568, GH80575, GH80579, GH80580, GH80581, GH80582 Exp 4/2020; GH80646, GH80664, GH80665, GH80684, GH80699, GH80700, GH80701, GH80746, GH80761, GH80765, GH80777 Exp 05/2020; GH80801, GH80823, GH80828, GH80878 Exp 06/2020; GH80967, GH80968, GH81033, GH81034 Exp 07/2020; GH81042, GH81154 Exp 08/2020; GH81255, GH81256, GH81288, GH81289, GH81310 Exp 10/2020 and GH81311 Exp 10/2020692538 vials
D-1125-2019Testosterone Cypionate Injection, USP, 1000 mg/10 mL (100 mg/mL), For intramuscular use only, 10 mL Vial, Multiple-Dose, Rx Only, Manufactured by: Cipla Ltd., Verna Goa, India, Manufactured for: Cipla USA, Inc., 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL 33323, NDC 69097-536-37.; Lots #: GH80216 Exp 1/2020; GH80322, GH80323 Exp 2/2020; GH90072 Exp 12/2020.75968 vials
Based on the official FDA remedy

What to do — step by step

  1. Stop Using Immediately

    Discard the vial if you have the recalled lot numbers listed in the recall notice.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the U.S.A.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 3.4 years after the firm started it.

1. Firm started the recall: Mar 22, 201912. FDA classified it Class II: Apr 15, 201923. Published in FDA’s Enforcement Report: Apr 24, 201934. FDA terminated the recall: Aug 16, 2022420192022
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1125-2019 (March 22, 2019) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1125-2019 to see it in context.
  • Plain-language summary written by qwen3:4b on October 5, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA